CHICAGO (Reuters) -Pfizer and BioNTech's COVID-19 vaccine is safe, effective and produces robust antibody responses in 12 to 15-year olds, they said on Wednesday, paving the way for them to seek U.S. and European approval in weeks to use the shot in this age group.
The read-out from a clinical trial, which puts the pair ahead of other Western vaccine developers in the quest to protect children, will likely allow for the use of the vaccine in that group before the next school year, Albert Bourla, Pfizer's chief executive, said in a statement.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
